Nanobiotix - ADR
NBTX
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.2B
Close$
$-5.31
123.9% downside
Current Fair Value
123.9% downsideOvervalued by 123.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.20 Billion |
|---|---|
| Enterprise Value | $1.23 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.5 |
| Beta | 0.57 |
| Outstanding Shares | 48,883,075 |
Return
| Return on Equity | 314.58% |
|---|---|
| Return on Assets | -81.83% |
| Return on Invested Capital | -165.35% |
Valuation & Multiples
| P/E Ratio | -19.31 |
|---|---|
| PEG | -3.54 |
| Price to Sales | - |
| Price to Book Ratio | -22.23 |
| Enterprise Value to Revenue | 98.9 |
| Enterprise Value to EBIT | -17.55 |
| Enterprise Value to Net Income | -12 |
| Total Debt to Enterprise | 0.12 |
| Debt to Equity | -4.28 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
September 30, 2026
EPS Estimate
$-0.13
Average shareholder expectationRevenue Estimate
$23.56 M
Average shareholder expectationNext Earnings Call
Expected Date
April 27, 2027
EPS Estimate
$0.06
Average shareholder expectationRevenue Estimate
$26.93 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 12.11%▲ 0.20% |
|---|---|
| Total Invested | $218.38M▲ 24.15% |
| Investors Holding | 19▲ 4.00% |
ESG Score
No data
About Nanobiotix
89 employees
CEO: Laurent Levy Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of cry...